Epilepsy is a common neurological condition, affecting 0.5-1% of the population worldwide. Epilepsy is a family of neurologic disorders, if not treated, is associated with progressively impaired cognition and function, brain damage, and other neurologic deficits. Conventional drugs like phenobarbital, primidone, phenytoin, carbamazepine, ethosuximide and benzodiazepine are widely used but exhibit an unfavorable side effect profile and failure to adequately control seizures. Thus, new concepts and original ideas for developing antiepileptic drugs are urgently needed. Quinazoline moiety is an important scaffold of many reported anticonvulsants. In the other hand, cyclooxygenase-2, an enzyme synthesizing the pro-inflammatory mediators, prostaglandins, has widely been reported to be induced during seizures and is considered to be a potential neurotherapeutic target for epilepsy management. In view of above-mentioned we design and synthesis new quinazoline derivatives with cyclooxygenase-2 inhibitory and anticonvulsant activity to control (prevent) seizures.
